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Introduction
In the recent years extensive interest has been devoted to study of ruthenium-based complexes as anticancer drugs, which is related to their lower toxicity when compared with conventional platinum drugs and their ability to overcome drug resistance. [2] [3] [4] very promising antitumor agent due to its selective inhibiting properties on the formation as well as growth of metastases with the negligible cytotoxic effect. [5] [6] [7] The NAMI-A complex has been found to be active in inhibiting formation and growth of lung, mammary and B16F10 melanoma metastasis. [8] [9] [10] [11] [12] However, this effect still remains unclear and brings about a question of why metastases and not the corresponding primary tumours are sensitive to this drug. Numerous in vivo and in vitro studies have shown multiple paths of NAMI-A action such as: arrest of the cell cycle at G 2 M pre-mitotic phase, apoptosis in endothelial cells, interaction with actin-type proteins on cell surface or extracellular matrix collagen, leading to inhibition of invasiveness. 3 However, the main molecular target of this complex is still unknown and literature reports suggest that overall effect may be resulting from multiple interactions outside and inside the cells. The confirmed antimetastatic properties of ruthenium(III)-dimethyl sulfoxide complexes bring about the need to understand the mechanism behind the therapeutic effect of these complexes. Due to involvement of NO in the several events contributed to tumour progression and the ability of ruthenium complexes to interact with NO 13 , a theory, that this signalling molecule is one of the targets of antimetastatic activity of NAMI-A has been raised. 1, 14 The NO plays an important role in progression of several human tumours as evidenced by the increased expression and activity of nitric oxide synthases (NOS). 15 The ruthenium complexes capable of acting both as NO scavengers and donors may interfere with NOrelated angiogenic process being a crucial step in the formation of metastases. Thus, the antimetastatic activity of NAMI-A and NAMI-A-type complexes was suggested to be related to their interaction with NO in vivo. 1 Indeed, it was shown that NAMI-A, KP1339 (Na[transRuCl 4 (Ind) 2 ], Ind -indazole) [16] [17] [18] and Ru(EDTA) complexes inhibit NO-dependent angiogenesis by capture of NO in vivo and in vitro without affecting the intracellular mechanism involved in proliferation. shown by Serli at al. 14, 22 Since temporary concentration and duration of NO exposure seems to have a crucial role in the tumorgenesis (stimulating or inhibiting) process, it is reasonable to assume that these complexes may have multiple roles in controlling NO levels. They may act either as NO scavengers or as NO donors by releasing NO in a subsequent reduction process. It is important to note that all studies concerning NO release via one electron reduction by nitrosyl ruthenium complexes similar in structure to NAMI-A have been performed so far in nonaqueous, aprotic media, thus the reaction conditions significantly different from physiological ones. Detailed studies on chemical behaviour of NAMI-A showed, that complex is relatively stable at pH=5.0 whereas at physiological pH (7.4) NAMI-A undergoes a series of hydrolysis reactions resulting in chloride dissociation and partial DMSO dissociation. 26, 27 Since reduction potential strongly depends on the nature of coordinated ligands, the aquation process occurring under physiological conditions leading to chlorides and DMSO release from ruthenium complexes will immensely affect the redox properties. Therefore, we decided to complete this missing part of the puzzle by investigating the reactivity of NAMI-A toward NO under physiological-like conditions. In this context, we report herein detailed spectroscopic, chromatographic and electrochemical characterization of the obtained ruthenium-nitrosyl derivatives. Furthermore, we studied the ability of NAMI-A -nitrosyl derivatives to release NO in consequence of reduction by biologically relevant reductants under physiologically mimicking conditions. Additional studies of NO binding to ruthenium complex were performed in the presence of albumin.
Experimental Section
Materials: All chemicals used in this study were of analytical reagent grade. NAMI-A was prepared following the published procedure, 28 and its purity was checked by elemental analyses and UV-vis spectroscopy. NO gas was purchased from Linde Gaz Polska Sp. z o.o.
and bubbled through concentrated KOH solution to remove higher nitrogen oxides (N 2 O 3 , NO 2 ), then passed through an Ascarite II column (NaOH on silica gel, Sigma Aldrich). Tris buffer (2-amino-2-(hydroxymethyl)-1,3-propanediol, > 99.8%), glutathione, ascorbic acid, NaNO 2 and NaCl were purchased from Sigma Aldrich. All solutions were prepared in deionized water. To follow NO release an amino-700 nitric oxide sensor connected to an inNO-T nitric oxide measuring system (Innovative Instruments, Inc.) was used.
Results and Discussion

Reaction of NAMI-A with NO -spectroscopic and chromatographic analysis
The reactivity of NAMI-A complex toward NO was studied under physiological mimicking conditions (pH = 7.4, 37 °C, 0.2 M NaCl). In order to monitor nitrosylation reaction, the time- This is due to the fact that coordination of NO to Ru centre requires opening up a coordination site which is provided by aquation process. The earlier studies on coordination of NO to It is important to note, that nitric oxide undergoes fast oxidation to nitrogen dioxide (NO 2 ) in the presence of oxygen which then hydrolysis to give nitrous acid (HNO 2 ) under aqueous conditions. All experiments with application of NO were performed under inert conditions, however, to confirm that peaks observed on chromatograms registered after mixing NAMI-A complex with NO come from nitrosyl derivatives and not from nitrite ones, NAMI-A solution was incubated for 30 min at 37 °C with NaNO 2 in the concentration ratio 1:2. Chromatograms registered after defined period of incubation were identical to the chromatograms obtained after the same time of hydrolysis of NAMI-A (results not shown). This observation indicates that registered spectral changes as well as chromatographically separated reaction products are indeed nitrosylation derivatives of studied ruthenium complex.
Influence of hydrolysis of NAMI-A on its reactivity toward NO
The results presented in the previous chapter are performed under conditions to inhibit hydrolysis before addition of NO. 33 Therefore, the initiated reactions comprise both the hydrolysis (due to introducing of buffer, which immediately changes the pH from ca. 5 to 7.4) and nitrosylation, which can occur simultaneously or consecutively. To assess the role of hydrolysis of NAMI-A complex on its reactivity toward nitric oxide the nitrosylation reaction was performed at various stage of hydrolysis process development. The ruthenium complex pre-equilibrated with Tris buffer (which corresponds with consecutive hydrolysis steps) for 7 and 30 min was subjected to reaction with NO and the observed UV-Vis spectral changes are presented in Figure 4 . In both cases disappearance of bands at 347 and 320 nm for hydrolyzed forms of NAMI-A complex is observed (Figure 4, insets) . Very similar UV-Vis spectra obtained for freshly prepared as well pre-equilibrated for 7 min ruthenium complex reacting with NO (Fig. S4 ) points out that, the nitrosylation of NAMI-A complex is preceded by formation of aqua derivative (small differences can arise from slightly higher amount of hydrolytic product in pre-equilibrated mixture, see Scheme 1). The formation of the same products was also confirmed by chromatographic studies (see further discussion). In contrast, the UV-Vis spectrum of the reaction mixture resulted from the addition of NO to NAMI-A complex, pre-equilibrated with Tris buffer for 30 min, displays bands between 420 and 500 nm characteristic for some products of NAMI-A hydrolysis (see Figure S1 ). It means that nitrosylation of this mixture takes place only partially, and some products of hydrolysis have rather week affinity toward NO. The presence of hydrolytic products was also confirmed by HPLC studies discussed below. Figure 5B ). Additionally, two peaks with much lower intensity appear at retention times of 2.3 and 2.5 min. Fast elution of these products suggests the formation of complexes with dissociated DMSO ligand, which is in accordance with suggested hydrolytic pathway. 27 Longer incubation time with buffer leads to diminishing of the peak at 3.6 min and increase in intensity of numerous less intensive peaks. After 30 min of incubation at 37 °C, intensity of the peaks at retention time of 2.3-2.5 min (not well resolved) meaningfully increased and a new peak at 3.1 min and broad peak at 4.7 min appeared ( Figure 5C ). The obtained chromatographic profile indicates the presence of the complex mixture of ruthenium aqua derivatives upon hydrolysis, which is in good agreement with previous studies. 26, 27, 29, 34 The UV-Vis spectra for most of the observed hydrolytic species are presented in insets in Figure 5 . They are all characterized by bands in the region of 300-400 nm, which are not found for ruthenium nitrosyl derivatives (see Figure   S2 and S3). This feature can help in identification of ruthenium nitrosyl complexes in the Serli et al. 22 The peak at retention time at 5.9 minutes has no equivalent at chromatograms for NAMI-A complex at various stages of hydrolysis and was ascribed to main nitrosylation product (see Figure S3 ). Accumulation of this product, in reaction mixture, decreases with increasing pre-incubation time since [RuCl 3 (DMSO)(H 2 O)(Im)])] is no longer available for nitrosylation, which is a consequence of progressive hydrolysis of NAMI-A. Pre-incubation longer than 30 min leads to complete disappearance of the peak at 5.9 min with concomitant increase of the intensity of several other peaks ascribed to nitrosyl derivatives of NAMI-A hydrolytic products ( Figure 6 ). The nitrosylation of this mixture occurs in a lesser extent as is manifested by the presence of a higher amount of hydrolytic products in comparison to reaction performed with NAMI-A complex freshly prepared or pre-equilibrated for 7 min (compare Fig. 6 and S3 ). 
NO-release
Previous studies on NO coordination to various Ru-DMSO-type complexes revealed formation of a diamagnetic Ru(II) centre bound to NO + . 14 Additionally, electrochemical measurements performed on series of Ru-nitrosyl complexes similar in structure to NAMI-A showed that this type of ruthenium complexes are redox active on NO + moiety and one electron reduction leads to NO liberation (as an example see Scheme 2). This gave rise to a hypothesis that antimetastatic mechanism of action of NAMI-A and related Ru-DMSO compounds may be due to interference in NO metabolism throughout nitric oxide binding and following releasing upon reduction in vivo. It is important to note that these studies were carried out in non-aqueous aprotic media (DMF) thus these results cannot be directly referred to physiological conditions. 14, 22 In order to verify this premise we carried out direct reduction studies with application of biologically relevant reductants: ascorbic acid, glutathione and sodium dithionite. It was expected that addition of the reductant into the solution containing (Ru Previous electrochemical studies showed that products of NAMI-A hydrolysis have redox potential in the range 0.187 V -0.597 V. 27 None of the waves observed during NAMI-A hydrolysis were registered after complex incubation with NO (see Figure S5) indicating lack of the electrochemically active Ru(III) centre in detectable concentration range. This indicates that formed product species are not electrochemically active in the potential range accessible for biological reductants such as ascorbic acid or glutathione.
NO binding in the presence of albumin
Since NAMI-A complex readily binds to the plasma proteins after intravenous administration 35 we checked its ability to bind NO when it was present in the form of NAMI- 
